Human and Veterinary Vaccines against Pathogenic Escherichia coli

Abstract

Pathogenic Escherichia coli constitute an important current problem of public health and animal production. Efforts have been made to fight the infections caused by these bacteria, and in this chapter, we present the progress made up to date in the vaccines generated for this purpose. Different vaccines have been tested against the pathotypes responsible for human diseases such as diarrhea and urinary infections. Also, the poultry market has deserved the effort of the researchers to obtain a product that fights the E. coli strains that cause diseases in them. Finally, advances are also presented for the zoonotic enterohemorrhagic E. coli (EHEC), which are a different problem due to their low importance as a disease factor in cattle, but they are a very important pathogen in humans. In several of these fields, authorized products have been developed and are currently being marketed.

Genetic characterization and clinicopathological features of <em>Escherichia coli</em> in neonatal septicemic calves

“…Finally, progress has been made on zoonotic enterohaemorrhagic E. coli (EHEC), which produces "Shiga Toxin", a different problem in cattle because of its minor role as a major pathogen that affects humans. However, approved products have been developed and are now being marketed in several of these areas (Larzábal et al, 2019).…”

O55 Polysaccharides Are Good Antigen Targets for the Formulation of Vaccines against O55 STEC and Capsulated aEPEC Strains

“…As a result, the management of HUS mainly involves supportive care [28][29][30]. Accordingly, several groups have been working with the aim to develop alternative treatments, such as the use of monoclonal antibodies to neutralize the action of Shiga toxins and the development of vaccines to prevent infection [31][32][33].…”

“…In relation to the development of vaccines against diarrheagenic E. coli, it should be taken into consideration that bacterial adhesion is a critical step that precedes colonization and infection. Therefore, an effective vaccine against STEC and other diarrheagenic E. coli strains has to generate antibodies that can inhibit the adhesion of these pathogens to the intestinal cells [31,32]. However, the variability encountered between the mechanisms of virulence of diarrheagenic E. coli, including strains that belong to the same serogroup, makes the development of vaccines against these pathogens a challenging task .…”